|Bid||6.35 x 100|
|Ask||6.36 x 200|
|Day's range||6.01 - 6.42|
|52-week range||4.45 - 7.88|
|PE ratio (TTM)||-4.65|
|Earnings date||11 May 2017 - 12 May 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||12.50|
BOSTON, June 28, 2017-- ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new immunotherapies, today announced the initiation of enrollment in the stereotactic arm of its Phase 1 multicenter ...
NEW YORK, NY / ACCESSWIRE / June 21, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ZIOPHARM Oncology, Inc. Here are 5 ETFs with the largest exposure to ZIOP-US. Comparing the performance and risk of ZIOPHARM Oncology, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)